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Sepsis is an important determinant of neonatal mortality and morbidity that accounts for a majority of neonatal deaths in the community [1]. Early recognition is very 
important but is notoriously difficult as the clinical signs of 
sepsis mimic almost every other neonatal problem. Blood 
culture which is the gold standard for the confirmation of 
neonatal sepsis is associated with high false negative rate, it 
being positive in only up to 50–60% of cases [2]. Hence, it is 
important to rely upon screening laboratory tests to assist us in 
the diagnosis of sepsis in both symptomatic babies and also in 
asymptomatic babies in the presence of risk factors for sepsis 
such as prematurity, prolonged rupture of membranes (PROM), 
maternal intrapartum fever >38oC, and asphyxia. Traditionally, 
neonatal sepsis is sub-classified into early onset and late onset 
based on the day of onset of symptoms, the cutoff being 72 h 
(3 days). The logic is that the probable acquisition of organisms 
is vertical (maternal vaginal flora) in the former, whereas 
horizontal (from the hospital environment) in the later. We 
will discuss the usefulness and limitations of available sepsis 
screen parameters in both these instances. This article is not 
an exhaustive theoretical structured review of all the mundane 
markers of neonatal sepsis for which the readers are referred 
to another recent article [3]. Rather, the focus is on providing 
practical tips to pediatricians in the all-important antibiotic 
therapy of neonatal sepsis by intelligent and judicious use of 
the routinely available sepsis screen markers.
REQUISITES OF AN IDEAL NEONATAL SEPSIS 
SCREEN
1. It should have 100% sensitivity and 100% negative predictive 
value (NPV) (i.e.) it should not miss any case of neonatal 
sepsis, but some overtreatment can be accepted.
2. It should be positive early in the course of the disease so that 
appropriate interventions that are initiated are effective in 
preventing morbidity and mortality.
3. It should have a short turn over time.
4. It should give consistent results when repeated in different 
centers.
5. It should be cost-effective and easier to perform and interpret.
No single test fulfills these criteria, and hence, commonly a 
battery of tests are grouped together to form a sepsis screen panel.
LABORATORY TESTS USED IN SEPSIS SCREENING
These are generally divided into hematological and non-
hematological parameters. The hematological parameters that 
are used in sepsis screening (Rodwell et al. hematological sepsis 
score) [4] are as follows:
1. Abnormal total leukocyte count (TLC)
2. Abnormal total neutrophil count
3. Abnormal immature neutrophil count (band count)
4. Abnormal immature: Total neutrophil count (I.T ratio >0.2)
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5. Abnormal immature: Mature neutrophil count >0.3
6. Decreased platelet count (<150,000)
7. Degenerative changes in the polymorphs (toxic granulations 
etc.).
A score of 3 or more is reported to have a sensitivity of 93% and 
an NPV of 98% [4]. It is important to bear in mind the physiological 
changes in the total leukocyte count and absolute neutrophil count 
(ANC) that occurs in the 1st week of life (Figs. 1 and 2) [5]. There 
is a physiological surge in the total leukocyte and ANC 6–12 h 
after delivery and base levels are reached after day 3 of life [5]. 
Hence, this hematological sepsis score is not generally used alone 
but almost always combined with acute phase reactants, especially 
the C-reactive protein (CRP).
ACUTE PHASE REACTANTS IN DIAGNOSIS OF 
NEONATAL SEPSIS
Acute phase reactants are proteins secreted by the liver in response 
to an acute stress such as sepsis, trauma, and surgery. CRP along 
with complete blood count is the widely used ritualistic sepsis 
screen panel [6]. Among the many other acute phase reactants 
evaluated as diagnostic markers, only procalcitonin (PCT) has 
been integrated in clinical practice [3].
CRP IN NEONATAL SEPSIS
CRP is the one universally used in sepsis screen panels. CRP 
coupled with complete blood count (CBC) is almost the ritualistic 
work up constituting the laboratory sepsis screen panel. It is 
an acute phase reactant with a half-life of 24–48 h in neonates 
and readily available test kits can estimate its levels [7]. A value 
of >0.6 mg/dl (6 mg/L) is considered as positive. In a recently 
published meta-analysis, CRP was found to have a sensitivity 
ranging from 30% to 80% but a higher specificity 83–100% at 
the onset of symptoms [3]. If done later say 24 h and 48 h after 
the neonate became symptomatic, there was an increasing trend 
in sensitivity (after 24 h) and specificity (after 48 h) [3]. It takes 
10–12 h for the levels to increase significantly after the onset of 
sepsis, and hence, it is a specific but relatively late marker of 
neonatal sepsis [6]. However, it cannot be used as a stand-alone 
marker as its sensitivity is low and levels can be significantly 
elevated with non-infectious causes such as trauma, meconium 
aspiration, and tissue injuries. Moreover, its levels are also 
influenced by gestational age with preterm infants having a poor 
CRP response following the onset of infection. Serial values are 
more useful than a single measurement in deciding the initiation 
and the duration of antibiotic therapy.
PCT IN NEONATAL SEPSIS
PCT is a glycoprotein consisting of 116 amino acids and upon 
cleavage in the C (parafollicular) cells of thyroid is converted into 
the active hormone calcitonin that consists of 32 amino acids [8]. 
PCT rises early during the illness by 4 h of onset of sepsis and 
returns to baseline sooner than CRP. PCT levels also show a 
physiological raise 24 h after delivery returning to baseline by 
the 3rd day, thereby having less specificity than CRP [6]. PCT 
response is more rapid than CRP, and hence, a PCT at 24 h of life 
can be a superior test to diagnose early-onset sepsis (EOS) [9]. 
However, beyond 24 h, the value of PCT in the diagnosis of 
EOS decreases due to its postnatal raise pattern. PCT levels are 
only minimally or not affected by trauma, meconium aspiration, 
and viral infections, and hence, it may be particularly useful in 
situations like diagnosing sepsis in a postsurgical neonate [10].
MICRO-ERYTHROCYTE SEDIMENTATION RATE 
(MICRO-ESR)
Micro-ESR is an easy bedside test that is performed using 
heparinized capillary tubes (75 mm long and 1.1 mm internal 
diameter) and is validated in many Indian studies. A fall of 
≥15 mm in the 1st h is considered as positive, and it is included 
in the pentad sepsis screen panel recommended by National 
Neonatology Forum (NNF) [11]. The NNF sepsis screen panel 
consists of the following five parameters (Positive screen is two 
or more parameters positive).
1. Leukopenia (TLC <5000)
2. Neutropenia (ANC <1800)
3. Immature: Total neutrophil count (I:T ratio >0.2)
Figure 2: Neutrophil count in healthy neonates over the 1st week of 
life
Figure 1: Total leukocyte count in healthy neonates
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4. Micro-ESR >15 mm in 1st h
5. Positive CRP.
CYTOKINES AND CELL SURFACE MARKERS AS 
ADJUNCTS TO DIAGNOSIS
Cytokines such as interleukin 6 (IL 6) and tumor necrosis factor 
have been evaluated in experimental studies [12]. Cytokines rise 
very early in the course of illness before even the acute phase 
reactants. IL 6 levels raise earlier than CRP and PCT in the course 
of neonatal sepsis and cord blood IL 6 levels are consistently 
elevated with EOS with sensitivity of 87–100% and NPV 
of 93–100% in studies [13,14]. Its half-life is short and levels 
normalize rapidly with treatment thus lowering its sensitivity at 
24 and 48 h [13]. Hence, it is an early and sensitive marker. IL 6 
and PCT might be the better combination to diagnose EOS while 
CRP ± PCT and CBC may be the choice of screening for late-
onset neonatal sepsis (LOS).
With advances in flow cytometry technology, cell surface 
markers in blood cells can be quantified and can be useful 
adjuncts in sepsis screen panels. Neutrophil surface markers CD 
11β and CD 64A have been found to be useful in diagnosing EOS 
and LOS, respectively [15]. Levels rise as sooner as 5 minutes 
after the onset of infection [16,17]. However, the usefulness of 
the cell surface markers in routine clinical practice is limited due 
to the cost factor and sophisticated technology and the unduly 
long processing time.
MOLECULAR AND GENOMIC TESTS
Gene-based molecular test to detect signature bacterial marker 
(16S rRNA) by real-time polymerase chain reaction (PCR) has 
been used to confirm bacterial sepsis in neonates as well as for 
genus characterization [18,19]. An Indian study found PCR for 
16S rRNA useful in neonatal sepsis with sensitivity of 100% and 
specificity of 95.6% [19].
CLINICAL SEPSIS SCREENING
For those in the underprivileged countries who cannot afford to 
have laboratory tests done a clinical sepsis screening has been 
devised. A WHO multicentric study had devised a clinical sepsis 
risk score using nine clinical parameters that can be recognized 
by community health workers to predict a serious bacterial illness 
in young infants [20]. A study from Chandigarh, India, evaluated 
the known clinical signs of neonatal sepsis using a set criteria 
of likelihood ratio of a positive test (LR+) >1 and a positive 
predictive value (PPV) of >30% identified the following seven 
clinical signs and suggested that a clinical risk score including 
these seven parameters will be beneficial to the clinicians to guide 
antibiotic treatment for LOS [21].
1. Abdominal distension
2. Increased pre-feed aspirates
3.  Hyperthermia (present on at least two occasions 1 h 
apart)




When this clinical risk score along with a laboratory, sepsis 
screen panel of four parameters (micro-ESR, CRP, ANC, 
and immature to mature leucocytes ratio) was evaluated in a 
validation cohort of 220 LOS episodes in 195 neonates in 2005, 
clinical sepsis score of one or more positive clinical signs at 0 h 
(the putative onset of LOS by the defined clinical signs) had a 
sensitivity of 90% and a NPV of 85.7%, whereas coupled with 
the laboratory sepsis screen panel the sensitivity increased to 95% 
and NPV to 90.6% [22]. A cutoff score of 1 had the highest NPV 
and negative likelihood ratio (85% and 0.44), whereas cutoff 
score of 2 or more had the best PPV and positive likelihood ratio 
(52% and 2.65) in diagnosis of LOS. In a subsequent study, to 
validate this clinical score in a cohort of very low birth weight 
babies, the authors report that the clinical score when coupled 
with a laboratory sepsis screen (2 or more positive of abnormal 
ANC, immature: Total neutrophil count, micro-ESR, and CRP) 
had a sensitivity of 95% and NPV of 90.6% [22].
In a study, 13% of well and ill-appearing neonate’s ≥34 weeks 
were evaluated for EOS and 11% were treated with antibiotics 
while only 0.04% of that cohort of 7004 neonates had culture-
proven sepsis [23]. Hence, the study evaluated the usefulness of 
a stratification strategy of term and late preterm neonates at risk 
of EOS using defined clinical risk factors, namely, the duration of 
rupture of membranes, highest maternal temperature, gestational 
age, Group B streptococcus carrier state, and intrapartum antibiotic 
prophylaxis, and newborn clinical examination parameters such 
as tachycardia, tachypnea, hyperthermia, need for vasopressors, 
respiratory distress, and need for breathing support such as 
oxygen therapy, CPAP, and ventilation [24]. Thus, the following 
three categories of neonates could be stratified, namely, clinical 
illness, equivocal presentation, and well-appearing babies with 
the respective pathways of treatment being empirical antibiotic 
therapy, evaluate, and antibiotics if indicated by the information 
gathered from the tests and continued clinical observation [24].
CHOICE OF SEPSIS SCREEN PANELS IN EOS AND 
LOS
Combination of CBC & CRP is the almost ritualistic and cost-
effective panel used routinely in neonatal units. Serial values help 
in decision-making process than a single measurement. Addition 
of PCT to this duo for the diagnosis of LOS may help in its earlier 
recognition and initiation of antibiotic therapy. Whereas PCT 
added to this duo in setting of EOS is helpful only if PCT is done 
at 24 h of life as its physiological rise after 24 h attenuates the 
advantage conferred by this added test. IL 6 (especially umbilical 
cord IL 6) and CD 11β may be of particular value in early 
diagnosis of EOS, whereas CD 64 may assist in earlier diagnosis 
of LOS, but these markers are at present experimental only and 
have not been adapted for routine clinical practice.
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ANTIBIOTIC USE AND LABORATORY SEPSIS 
SCREEN
The universal rule is that blood culture and cultures of other body 
fluids like cerebrospinal fluid and urine (as applicable) should be 
taken before initiation of antibiotic therapy in any newborn and 
antibiotics should be continued until culture results are known 
and thereafter, in case of positive cultures, duration of antibiotic 
therapy is dictated by the isolated pathogen. However, in the 
remaining culture negative cases (≈50%), decision has to be made 
making the best use of commonly available laboratory sepsis 
screen markers. The following guidelines are suggested in such 
situations.
1. In the symptomatic newborn, antibiotics should not be 
withheld on the face of a negative sepsis screen as none of the 
available screens has 100% NPV. However, antibiotics can 
be stopped in such a situation once the cultures (blood and 
cerebrospinal fluid [CSF]) are negative and a repeat sepsis 
screen remains negative.
2. In the symptomatic newborn with a positive sepsis screen 
whose cultures are also negative, antibiotics should be 
continued for 24–48 h after the repeat screen is negative.
3. In the asymptomatic newborn with a negative sepsis screen 
in whom antibiotics are started because of the presence of 
major or multiple perinatal risk factors for sepsis, antibiotics 
can be safely stopped once cultures are negative and a repeat 
screen is also negative.
4. In the asymptomatic newborn with a negative sepsis screen 
in the presence of only a single minor risk factor for sepsis, 
antibiotics can be withheld with the provision that the neonate 
should be observed for the next 24 h for symptoms and signs 
of sepsis.
5. In the asymptomatic newborn with a positive sepsis screen, 
antibiotics should be administered and continued until the 
cultures are reported negative or for 24–48 h after a negative 
repeat screen whichever is later.
CASE STUDIES TO ILLUSTRATE ANTIBIOTIC USE 
IN NEONATES
1. Term/3.2 kg/male, vaginal delivery, presents at 36 h with 
poor feeding, lethargy, and grunting. PROM for 28 h.
 • Symptomatic newborn, EOS picture
 •  Sepsis screen, blood culture, lumbar puncture, chest 
X-ray, and start antibiotics till review with culture 
results.
 •  Culture positive cases, antibiotic therapy will be based 
on culture results irrespective of sepsis screen. Blood 
culture positive: 10–14 days based on the organism and 
clinical response. CSF culture positive: 14–21 days
 •  Culture-negative and first sepsis screen negative: 
Antibiotics can be safely stopped if a repeat sepsis 
screen (at least 24 h apart from the first screen) remains 
negative
 •  Culture-negative and first sepsis screen positive: 
Continue antibiotics until 24–48 h after repeat sepsis 
screens are negative.
2. Term/3 kg/female, vaginal delivery with a history of PROM 
for 30 h, asymptomatic, and feeding well.
 •  Observe the baby for 24–48 h for symptoms of sepsis. 
No antibiotics
 •  If the baby becomes symptomatic anytime then manage 
as discussed with case 1.
3. 34 weeks/2.1 kg/male, asymptomatic, PROM 3 days
 • Two significant risk factors for EOS.
 •  Sepsis screen, blood culture, and antibiotics. Some 
clinicians will do lumbar puncture in this setting only if 
screen is positive or blood culture is positive
 •  If culture positive then antibiotics will be guided by 
culture results as discussed in case 1.
 •  If culture negative then follows the same approach as 
discussed in case 1.
4. 30 weeks/1.6 kg/female, ventilated for 4 days for hyaline 
membrane disease presents on the 7th day with apnea and 
episodes of duskiness.
 • LOS picture, symptomatic
 •  Sepsis screen, blood culture, LP, chest X-ray, and start 
antibiotics
 •  Culture positive = 10–14 days for blood culture, 
14–21 days for CSF
 •  Culture-negative = antibiotics till 24–48 h after a negative 
sepsis screen or empirically for 5–7 days whichever is 
later.
5. Term/2.9 kg/male, no risk factors, on breastfeed presents on 
the 5th day with tachypnea and vomiting. Blood gas: 7.51/PO2 
68/PCO2 28/HCO3 19 (respiratory alkalosis)
 • LOS like picture, symptomatic
 •  Sepsis screen, blood culture, LP, chest X-ray, and start 
antibiotics
 • Further decisions for antibiotic therapy as in case 1
 •  In the real clinical scenario, for this baby, cultures were 
negative, screens repeatedly negative but baby’s clinical 
condition deteriorated despite antibiotics. On further 
evaluation, this baby was diagnosed with inborn error of 
metabolism (urea cycle disorder).
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